Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Nov;107 Suppl 1(0 1):74-82.
doi: 10.1111/j.1360-0443.2012.04041.x.

Opioid dependence during pregnancy: relationships of anxiety and depression symptoms to treatment outcomes

Margaret M Benningfield  1 , Mary S Dietrich, Hendrée E Jones, Karol Kaltenbach, Sarah H Heil, Susan M Stine, Mara G Coyle, Amelia M Arria, Kevin E O'Grady, Gabriele Fischer, Peter R Martin
Affiliations
Randomized Controlled Trial

Opioid dependence during pregnancy: relationships of anxiety and depression symptoms to treatment outcomes

Margaret M Benningfield et al. Addiction. 2012 Nov.

Abstract

Aims: To examine the relationship of anxiety and depression symptoms with treatment outcomes (treatment discontinuation, rates of ongoing use of illicit drugs and likelihood of preterm delivery) in opioid-dependent pregnant women and describe their use of psychotropic medications.

Design and setting: Secondary data analysis from a randomized clinical trial of treatment for opioid dependence during pregnancy.

Participants: A total of 175 opioid-dependent pregnant women, of whom 131 completed treatment.

Measurements: Symptoms of anxiety and depression were captured with the 15-item Mini International Neuropsychiatric Interview (MINI) screen. Use of illicit drugs was measured by urine drug screening. Preterm delivery was defined as delivery prior to 37 weeks' gestation. Self-reported use of concomitant psychotropic medication at any point during the study was recorded.

Findings: Women reporting only anxiety symptoms at study entry were more likely to discontinue treatment [adjusted odds ratio (OR) = 4.56, 95% confidence interval (CI) : 1.91-13.26, P = 0.012], while those reporting only depression symptoms were less likely to discontinue treatment (adjusted OR = 0.14, 95% CI : 0.20-0.88, P = 0.036) compared to women who reported neither depression nor anxiety symptoms. No statistically significant between-group differences were observed for ongoing illicit drug use or preterm delivery. A majority (61.4%) of women reported use of concomitant psychotropic medication at some point during study participation.

Conclusions: Opioid agonist-treated pregnant patients with co-occurring symptoms of anxiety require additional clinical resources to prevent premature discontinuation.

Trial registration: ClinicalTrials.gov NCT00271219.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interest:

This study was funded by the National Institute on Drug Abuse and National Center for Research Resources, National Institutes of Health.

The clinical trial was registered with ClinicalTrials.gov (Identifier: NCT00271219; Title: RCT Comparing Methadone and Buprenorphine in Pregnant Women).

H.J. discloses that she has received reimbursement for time and travel from Reckitt Benckiser.

G.F. discloses that she has received financial support and honoraria for presentations from Reckitt Benckiser, as well as financial support and honoraria for presentations from Schering Plough.

KEO’G discloses that he has received reimbursement for time from Reckitt Benckiser

Figures

Figure 1
Figure 1. Treatment discontinuation by symptom groups (n = 175)
Opioid-dependent pregnant women reporting anxiety only were more likely and those reporting depression only were less likely to discontinue treatment prior to delivering an infant than women reporting symptoms in neither category. Symptoms of anxiety and depression were determined at study entry using the 15-item MINI screen. Width of each bar is proportional to the number of participants in each group. Error bars represent 95% confidence interval.
See this image and copyright information in PMC

References

    1. Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, et al. Neonatal Abstinence Syndrome after Methadone or Buprenorphine Exposure. N Eng J Med. 2010;363:2320–31. - PMC - PubMed
    1. Jones HE, Martin PR, Heil SH, Kaltenbach K, Selby P, Coyle MG, et al. Treatment of opioid-dependent pregnant women: clinical and research issues. J Subst Abuse Treat. 2008;35:245–59. - PMC - PubMed
    1. Benningfield MM, Arria AM, Kaltenbach K, Heil SH, Stine SM, Coyle MG, et al. Co-occurring psychiatric symptoms are associated with increased psychological, social, and medical impairment in opioid dependent pregnant women. Am J Addict. 2010;19:416–21. - PMC - PubMed
    1. Fitzsimons HE, Tuten M, Vaidya V, Jones HE. Mood disorders affect drug treatment success of drug-dependent pregnant women. J Subst Abuse Treat. 2007;32:19–25. - PubMed
    1. Kessler RC, Mcgonagle KA, Zhao SY, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-Month Prevalence of DSM-III-R Psychiatric-Disorders in the United-States - Results from the National-Comorbidity-Survey. Arch Gen Psychiatry. 1994;51:8–19. - PubMed

Publication types

MeSH terms

Associated data